Aptevo Therapeutics Surges on Breakthrough AML Treatment Results

Aptevo Therapeutics Inc. (APVO) surged 46.10% during after-hours trading on Wednesday following breakthrough clinical results demonstrating its drug's potential to redefine frontline AML treatment. The biotech company reported that all patients in Cohort 3 of its Phase 1b/2 RAINIER trial went into complete remission with no dose-limiting toxicities or cytokine release syndrome. The frontline AML market is a multi-billion-dollar opportunity, with current standard treatments achieving lower remission rates than those seen in the RAINIER trial.